一种有前途的新型HBV血清标志物——HBcrAg

陈恩强; 唐红

doi:10.3969/j.issn.1001-5256.2019.10.006

一种有前途的新型HBV血清标志物——HBcrAg

DOI: 10.3969/j.issn.1001-5256.2019.10.006

陈恩强,
唐红

四川大学华西医院感染性疾病中心

详细信息

中图分类号: R512.62
计量
- 文章访问数: 2655
- HTML全文浏览量: 56
- PDF下载量: 493
- 被引次数: 0
出版历程
- 收稿日期: 2019-08-26
- 出版日期: 2019-10-20

Hepatitis B virus core-related antigen:A promising new serum marker for hepatitis B virus

Center of Infectious Diseases,West China Hospital of Sichuan University

摘要

摘要: 乙型肝炎核心相关抗原（HBcrAg）是HBV新的血清标志物,由HBV前C/C区基因编码的几种抗原共同组成,包括HBcAg、HBeAg和P22cr前体蛋白。HBcrAg与HBsAg定量检测结果的相关性一般,彼此不能互相取代。血清中HBcrAg水平可反映慢性乙型肝炎患者肝细胞内cccDNA的含量及转录活性,也可能反映整合HBV DNA的转录活性。此外,HBcrAg可用于评价核苷（酸）类似物和PEG-IFN的抗病毒效果,预测核苷（酸）类似物治疗患者停药后的复发风险、肝细胞癌的发展和术后复发风险。据此,目前认为HBcrAg是一种非常有前途的新型HBV血清标志物。
- 乙型肝炎病毒 /
- 乙型肝炎核心抗原 /
- 乙型肝炎核心相关抗原 /
- DNA,环状
Abstract: Hepatitis B virus core-related antigen(HBcrAg) is a new serum biomarker for hepatitis B virus(HBV) and is composed of several antigens encoded by the pre-C/C region gene of HBV,including HBcAg,HBeAg,and P22 cr precursor protein. There is a poor correlation between HBcrAg and HBsAg and they cannot replace each other. Serum HBcrAg level can reflect the content and transcriptional activity of cccDNA in hepatocytes of patients with chronic hepatitis B,as well as the transcriptional activity of integrated HBV DNA. In addition,HBcrAg can be used to evaluate the antiviral effect of nucleos(t) ide analogues and pegylated interferon-and predict recurrence risk after withdrawal of nucleos(t) ide analogues and the development risk and recurrence of hepatocellular carcinoma after surgery. Therefore,serum HBcrAg is a promising new serum marker for HBV.
- hepatitis B virus /
- hepatitis B core antigens /
- hepatitis B core-related antigen /
- DNA,circular

HTML全文

参考文献(20)

[1] MAK LY,WONG DK,CHEUNG KS,et al. Review article:Hepatitis B core-related antigen(HBcrAg):An emerging marker for chronic hepatitis B virus infection[J]. Aliment Pharmacol Ther,2018,47(1):43-54.

[2] ROKUHARA A,TANAKA E,MATSUMOTO A,et al. Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core-related antigen; a marker distinct from viral DNA for monitoring lamivudine treatment[J]. J Viral Hepat,2003,10(4):324-330.

[3] NASSAL M. HBV cccDNA:Viral persistence reservoir and key obstacle for a cure of chronic hepatitis B[J]. Gut,2015,64(12):1972-1984.

[4] LUCIFORA J,PROTZER U. Attacking hepatitis B virus cccDNA—The holy grail to hepatitis B cure[J]. J Hepatol,2016,64(1 Suppl):s41-s48.

[5] CHEN EQ,FENG S,WANG ML,et al. Serum hepatitis B core-related antigen is a satisfactory surrogate marker of intrahepatic covalently closed circular DNA in chronic hepatitis B[J].Sci Rep,2017,7(1):173.

[6] CHEN EQ,WANG ML,TAO YC,et al. Serum HBcrAg is better than HBV RNA and HBsAg in reflecting intrahepatic covalently closed circular DNA[J]. J Viral Hepat,2019,26(5):586-595.

[7] WANG ML,LIAO J,WEI B,et al. Comparison of hepatitis B virus core-related antigen and hepatitis B surface antigen for predicting HBe Ag seroconversion in chronic hepatitis B patients with pegylated interferon therapy[J]. Infect Dis(Lond),2018,50(7):522-530.

[8] NIU JQ. Serum hepatitis B core-related antigen can predict outcome as a satisfactory surrogate marker in chronic hepatitis B patients[R]. San Francisco:AASLD,2018.

[9] SONG G,YANG R,RAO H,et al. Serum HBV core-related antigen is a good predictor for spontaneous HBe Ag seroconversion in chronic hepatitis B patients[J]. J Med Virol,2017,89(3):463-468.

[10] SETO WK,WONG DK,FUNG J,et al. Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B[J]. Clin Microbiol Infect,2014,20(11):1173-1180.

[11] MAASOUMY B,WIEGAND SB,JAROSZEWICZ J,et al. Hepatitis B core-related antigen(HBcrAg)levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D[J]. Clin Microbiol Infect,2015,21(6):606. e1-10.

[12] Drafting Committee for Hepatitis Management Guidelines and the Japan Society of Hepatology. JSH guidelines for the management of hepatitis B virus infection[J]. Hepatol Res,2014,44(Suppl 1):1-58.

[13] WANG ML,CHEN EQ,TAO CM,et al. Pronounced decline of serum HBs Ag in chronic hepatitis B patients with long-term effective nucleos(t)ide analogs therapy[J]. Scand J Gastroenterol,2017,52(12):1420-1426.

[14] WANG ML,DENG R,CHEN EQ,et al. Performance of serum HBcrAg in chronic hepatitis B patients with 8-year nucleos(t)ide analogs therapy[J]. Clin Res Hepatol Gastroenterol,2019,43(3):301-309.

[15] WANG ML,CHEN EQ,TAO CM,et al. Letter:Serum HBcrAg is a useful marker for disease monitoring,predicting treatment response and disease outcome of chronic hepatitis B virus infection[J]. Aliment Pharmacol Ther,2018,47(12):1719-1720.

[16] TADA T,KUMADA T,TOYODA H,et al. HBcrAg predicts hepatocellular carcinoma development:An analysis using time-dependent receiver operating characteristics[J]. J Hepatol,2016,65(1):48-56.

[17] CHEUNG KS,SETO WK,WONG DK,et al. Relationship between HBsAg,HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy[J]. J Viral Hepat,2017,24(8):654-661.

[18] HOSAKA T,SUZUKI F,KOBAYASHI M,et al. HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy[J]. Liver Int,2010,30(10):1461-1470.

[19] HOSAKA T,SUZUKI F,KOBAYASHI M,et al. Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues[J]. Aliment Pharmacol Ther,2019,49(4):457-471.

[20] TO WP,MAK LY,WONG DK,et al. Hepatitis B core-related antigen levels after HBe Ag seroconversion is associated with the development of hepatocellular carcinoma[J]. J Viral Hepat,2019.[Epub ahead of print]

施引文献

资源附件(0)

访问统计